1,734 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Fox Run Management L.L.C.

Key Points

• Fox Run Management L.L.C. acquired a new stake in Regeneron Pharmaceuticals, purchasing 1,734 shares valued at approximately $1,100,000 in the first quarter.
• Regeneron Pharmaceuticals reported $12.89 earnings per share for the last quarter, significantly exceeding analysts' expectations of $8.43.
• The company announced a quarterly dividend of $0.88 per share, with the next payment scheduled for September 3rd, contributing to a dividend yield of 0.6%.

Fox Run Management L.L.C. acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,734 shares of the biopharmaceutical company's stock, valued at approximately $1,100,000.

Other hedge funds have also made changes to their positions in the company. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares during the last quarter. Costello Asset Management INC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $27,000. Tompkins Financial Corp acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $32,000. Finally, Curat Global LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $32,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on REGN. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price on the stock. in a research report on Friday, August 1st. Argus lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Citigroup reaffirmed a "buy" rating and issued a $650.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Cantor Fitzgerald began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $829.65.

Regeneron Pharmaceuticals Stock Down 0.1%

NASDAQ:REGN traded down $0.5350 during mid-day trading on Tuesday, hitting $573.3750. The company had a trading volume of 509,383 shares, compared to its average volume of 1,106,841. The business has a fifty day simple moving average of $545.33 and a 200-day simple moving average of $593.59. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The firm has a market capitalization of $60.77 billion, a price-to-earnings ratio of 14.47, a PEG ratio of 1.93 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same period in the previous year, the company earned $11.56 earnings per share. The company's revenue for the quarter was up 3.6% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.